Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454524 | 1.00 | TSHR (0.44) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL19379407 | 1.00 | TSHR (0.44) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL940895 | 0.85 | TSHR (0.43) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL2928506 | 0.78 | PTGS1 (0.43) | TSHRALDH1A1TDP1ALOX15RECQL | |
| SCHEMBL2928510 | 0.78 | PTGS1 (0.43) | TSHRALDH1A1TDP1ALOX15RECQL | |
| SCHEMBL2931476 | 0.78 | PTGS1 (0.43) | TSHRALDH1A1TDP1ALOX15RECQL | |
| SCHEMBL529628 | 0.77 | TSHR (0.44) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL529630 | 0.77 | TSHR (0.44) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL12486634 | 0.74 | LMNA (0.35) | PTGS1LMNA | |
| SCHEMBL12486635 | 0.74 | LMNA (0.35) | PTGS1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787900-B2 | Biodegradable sustainable polyesters | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-10-17 | — | — | US | claimed |
| US-20230151142-A1 | BIODEGRADABLE SUSTAINABLE POLYESTERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-05-18 | — | — | US | claimed |
| WO-2023081515-A1 | BIODEGRADABLE SUSTAINABLE POLYESTERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-11 | — | — | WO | claimed |
| US-20160355843-A1 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2016-12-08 | — | — | US | claimed |
| US-20160355844-A1 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2016-12-08 | — | — | US | claimed |
| CN-104769119-A | Methods for biosynthesizing 1,3 butadiene | INVISTA TECH SARL | 2015-07-08 | — | — | CN | claimed |
| EP-2861745-A2 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | Invista Technologies S.à.r.l. (CH) | 2015-04-22 | — | — | EP | claimed |
| CN-104321434-A | Methods for biosynthesizing 1,3butadiene | INVISTA TECH SARL | 2015-01-28 | — | — | CN | claimed |
| EP-2785848-A2 | METHODS FOR BIOSYNTHESIZING 1,3BUTADIENE | INVISTA Technologies S.à.r.l. (CH) | 2014-10-08 | — | — | EP | claimed |
| WO-2013188546-A2 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA TECHNOLOGIES S.À.R.L. (CH) | 2013-12-19 | — | — | WO | claimed |
| WO-2013082542-A2 | METHODS FOR BIOSYNTHESIZING 1,3BUTADIENE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2013-06-06 | — | — | WO | claimed |
| US-12606808-B2 | Mirror nucleic acid replication system | TSINGHUA UNIVERSITY (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| US-12325884-B2 | Riboswitch-based fluoride sensing in cell-free extract | NORTHWESTERN UNIVERSITY (US) | 2025-06-10 | — | — | US | disclosed |
| CN-1205032-A | Novel microorganism and method for environmental purification using the same | TOYOTA MOTOR CO LTD (JP) | 1999-01-13 | — | — | CN | disclosed |
| EP-0390102-A2 | Process for the preparation of pyridine-2,3-dicarboxylic acids | CELGENE CORPORATION (US) | 1990-10-03 | — | — | EP | disclosed |
| US-4654303-A | Construction of novel mutant microorganisms | CELANESE CORPORATION (US) | 1987-03-31 | — | — | US | disclosed |
| EP-0138391-A1 | Construction of novel mutant micro-organisms | CELGENE CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4173692-A | ORGANIC ALKALI METAL SALT AND ORGANOTIN COMPOUND AS CATALYST | M&T CHEMICALS INC. (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606808-B2 | Mirror nucleic acid replication system | NOP2, NSUN3, MED23 | TSHR 1965/4885TP53 1377/4885EGLN1 4848/4885 |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | TSHR 1704/4885TP53 2128/4885EGLN1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.